Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Fractionation Clear all
Recruiting Not applicable Interventional

Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study

NCT04371913
View directory record Official record
Conditions
Breast Cancer
Interventions
600cGY x 5 fractions APBI, 270cGy x 15 fractions WBRT
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Recruiting Phase 2 Interventional

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

NCT06160206
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Retifanlimab
Biological · Procedure · Other + 1 more
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 30, 2026, 3:17 PM EDT
Withdrawn Phase 2 Interventional

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

NCT05161533
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 30, 2026, 3:17 PM EDT
Active, not recruiting Not applicable Interventional

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

NCT06055881
View directory record Official record
Conditions
Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
Interventions
Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT), Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

NCT03715946
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma
Interventions
Nivolumab Injection, Radiotherapy (RT)
Drug · Radiation
Lead sponsor
Robert L. Ferris, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Portland, Oregon • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 30, 2026, 3:17 PM EDT
Active, not recruiting Not applicable Interventional Results available

Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer

NCT05139368
View directory record Official record
Conditions
Cervical Carcinoma, Endometrial Carcinoma
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Not applicable Interventional

Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors

NCT00042367
View directory record Official record
Conditions
Brain Tumors
Interventions
Induction therapy (Regimen 1, Course 1, Cycle A1, Regimen 1, Course 1, Cycle A2 (Days 22 - 42), Cycle B, Regimen 1, Course 2, Intrathecal Mafosfamide, Regimen 1 Course 2, IT mafosfamide, Regimen 2, Course 1, Regimen 2, Course, 1, Cycle C1, Regimen 2, Course 2, radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 36 Months
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Durham, North Carolina • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated Not applicable Interventional Results available

Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma

NCT02672033
View directory record Official record
Conditions
Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Interventions
Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Radiation · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NCT02819843
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Other Solid Tumors
Interventions
TALIMOGENE LAHERPAREPVEC (TVEC), Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Middletown, New Jersey • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation

NCT02783690
View directory record Official record
Conditions
Breast Cancer
Interventions
Hypofractionation
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 30, 2026, 3:17 PM EDT
Completed No phase listed Observational

Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome

NCT03383107
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

NCT03043807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00265941
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, Accelerated Fractionation by Concomitant Boost, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
363
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 255 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated Phase 2 Interventional

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

NCT04862455
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Hafnium Oxide-containing Nanoparticles NBTXR3, Hypofractionated Radiation Therapy, Pembrolizumab, Stereotactic Body Radiation Therapy
Other · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

NCT01732640
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Afatinib, Paclitaxel, Carboplatin, Cisplatin, Intensity Modulated Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bovine Milk Oligosaccharide Study

NCT01814540
View directory record Official record
Conditions
Healthy
Interventions
Bovine Milk Oligosaccharide, Placebo Glucose Polymer
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 30, 2026, 3:17 PM EDT
Active, not recruiting Not applicable Interventional

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

NCT02698254
View directory record Official record
Conditions
Recurrent Brain Neoplasm
Interventions
Bevacizumab, Quality-of-Life Assessment, Radiation Therapy
Biological · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies

NCT01682226
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Lymphoma
Interventions
CliniMACS Fractionation system (Arm A), CliniMACS Fractionation system (Arm B), Haploidentical donor CD34+ cells
Device · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 30, 2026, 3:17 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

NCT06979492
View directory record Official record
Conditions
Sickle Cell Disease, Pregnancy Related
Interventions
Prophylactic Transfusion Intervention group: Transfusion, Control group
Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Recruiting Phase 2 Interventional

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

NCT06078709
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Esophagogastroduodenoscopy, Fluorouracil, Hypofractionated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Positron Emission Tomography, Survey Administration, Docetaxel, Durvalumab
Procedure · Drug · Radiation + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Early Phase 1 Interventional

Radiation Therapy in Treating Women With Invasive Breast Cancer

NCT00301041
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, adjuvant therapy, radiation therapy
Other · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 30, 2026, 3:17 PM EDT
Active, not recruiting Early Phase 1 Interventional

Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer

NCT04648904
View directory record Official record
Conditions
Invasive Breast Cancer, Post-mastectomy
Interventions
Radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1Phase 2 Interventional

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

NCT04601831
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Focal radiation therapy (RT)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 30, 2026, 3:17 PM EDT
Recruiting Phase 2 Interventional

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

NCT04990921
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palliative Radiation and Pembrolizumab
Combination Product
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 30, 2026, 3:17 PM EDT